We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBarinthus Biotherapeutics plc

Barinthus Biotherapeutics plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-12T15:47:08.249438Z
Market Cap
24.10M

Momentum Score

…

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.51
Low
2.91
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Barinthus Biotherapeutics plc is a NASDAQ-listed biopharmaceutical company; publicly available information about its pipeline and operations is limited. Long-term growth may depend on progress in clinical programs, successful regulatory milestones and commercialization partnerships, which could support value creation for investors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.13M
Debt / Equity
0.15
ROE
-65.02%
Net Debt
-59.17M
ROCE
-61.46%
Diluted EPS TTM
-1.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -68.79M -61.23M -76.82M 0.85M -51.14M
Minority interest 0.03M 0.11M 0.08M 0.02M -0.25M
Net income -66.43M -61.07M -73.63M 5.34M -50.87M
Selling general administrative 40.83M 29.67M 39.84M 6.39M 25.12M
Selling and marketing expenses - - 0.15M - -
Gross profit -5.86M 14.97M 0.80M 44.70M 0.27M
Reconciled depreciation 5.84M 5.80M 5.17M 4.32M 0.60M
Ebit -54.18M -61.17M -76.49M 0.87M -40.89M
Ebitda -48.34M -55.37M -71.06M 5.19M -40.28M
Depreciation and amortization 5.84M 5.80M 5.43M 4.32M 0.60M
Non operating income net other - - - - -3.25M
Operating income -54.19M -67.97M -84.24M -4.04M -45.22M
Other operating expenses 54.19M 82.94M 85.04M 47.50M 41.49M
Interest expense 0.05M 0.05M 0.03M 0.02M 2.67M
Tax provision -0.17M -0.04M -4.27M -4.47M -0.03M
Interest income 1.96M 2.68M 3.63M 3.10M 0.00M
Net interest income 1.91M 2.62M 3.59M 3.08M -2.67M
Income tax expense -0.20M -0.04M -3.09M -4.47M -0.03M
Total revenue 0.00M 14.97M 0.81M 44.70M 0.27M
Total operating expenses 48.34M 82.94M 85.04M 47.50M 41.49M
Cost of revenue 5.86M 5.80M 0.00M - -
Total other income expense net -14.60M 6.74M 7.42M 0.57M -7.25M
Net income from continuing ops -66.46M -61.18M -77.32M 5.32M -51.11M
Net income applicable to common shares - - - - -50.87M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 98.17M 160.33M 214.51M 270.20M 280.71M
Intangible assets 14.29M 21.95M 25.11M 28.27M 31.43M
Other current assets 6.03M 2.08M 9.91M 8.27M 6.46M
Total liab 23.88M 30.19M 27.51M 27.00M 28.15M
Total stockholder equity 74.21M 130.03M 186.78M 242.90M 252.12M
Other current liab 6.25M 7.11M 9.21M - -
Common stock 0.00M 0.00M 0.09M - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -304.09M -237.66M -176.59M -103.24M -108.58M
Good will - 0.00M 12.21M 12.21M 12.63M
Cash 70.46M 110.66M 142.09M 194.38M 214.05M
Total current liabilities 10.02M 15.66M 12.60M 12.24M 11.16M
Current deferred revenue 1.40M 1.74M - - -
Net debt -59.17M -98.66M -129.11M - -
Short term debt 2.02M 1.92M 1.78M - -
Short long term debt - - - - 0.16M
Short long term debt total 11.28M 12.01M 12.98M - -
Other stockholder equity 393.94M 393.56M 386.60M - -
Total current assets 77.79M 125.74M 156.91M 213.04M 226.76M
Net receivables 1.30M 13.00M 4.91M 5.85M 0.02M
Inventory - - 0.00M - -
Accounts payable 0.35M 2.47M 1.60M 3.75M 2.42M
Accumulated other comprehensive income -15.73M -25.87M -23.32M - -
Non currrent assets other 0.93M 0.88M 0.88M 0.98M 0.80M
Non current assets total 20.38M 34.59M 57.60M 57.16M 53.95M
Capital lease obligations 11.28M 12.01M 12.98M 8.77M 7.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.89M -6.15M -5.75M -12.91M
Change to liabilities - - - - 0.89M
Total cashflows from investing activities 0.42M -0.89M - - -12.91M
Total cash from financing activities 0.00M 2.16M 1.87M 0.33M 222.74M
Change to operating activities - - - - -4.15M
Net income -66.46M -61.18M -73.45M 5.32M -51.11M
Change in cash -40.55M -29.69M -52.30M -19.67M 170.79M
Begin period cash flow 112.40M 142.09M 194.38M 214.05M 43.27M
End period cash flow 71.85M 112.40M 142.09M 194.38M 214.05M
Total cash from operating activities -47.98M -28.94M -50.92M -14.43M -32.58M
Issuance of capital stock 0.00M 2.16M 2.41M 0.48M 228.01M
Depreciation 5.84M 5.80M 5.43M 4.32M 0.60M
Other cashflows from investing activities -0.00M - - - -11.77M
Change to inventory - - - -0.65M -4.15M
Change to account receivables 6.42M -2.35M 5.80M -5.83M 0.56M
Sale purchase of stock - - - - 100.60M
Other cashflows from financing activities -0.00M 2.16M -0.16M -5.75M 119.97M
Change to netincome - - - - 23.95M
Capital expenditures 0.04M 0.89M 5.41M 6.14M 1.15M
Change receivables - - - - 0.56M
Cash flows other operating - - - - -7.47M
Cash and cash equivalents changes - - - - 177.25M
Change in working capital -0.36M 2.60M 6.17M -5.52M -7.18M
Stock based compensation 0.47M 4.71M 5.05M 9.88M 16.49M
Other non cash items 12.70M 19.18M 8.94M -24.09M 8.74M
Free cash flow -48.02M -29.83M -56.34M -20.57M -33.73M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.

20400 Century Boulevard, Germantown, MD, United States, 20874

443 917 0966

https://www.barinthusbio.com

14

Name Title Year Born
Mr. William J. Enright MBA CEO & Director 1962
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 1979
Mr. Graham Griffiths Chief Business Officer 1980
Ms. Sarah Gilbert Co-Founder NA
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor NA
Ms. Gemma Brown CFO & Company Secretary 1991
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations NA
Bernie McDonald Head of IP NA
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies NA
Mr. William James Enright MBA CEO, Director, Secretary & Principal Financial Officer 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…